Last updated: March 1, 2026
What is the Scope of JP2015062420?
Patent JP2015062420 concerns a pharmaceutical composition formulated for targeted delivery—most likely in the oncology or neurology domain, based on available classification data. The patent covers a specific combination of active ingredients, excipients, and delivery mechanisms designed to enhance bioavailability and site-specific action.
Scope Summary:
- Core Focus: Composition comprising a certain drug compound (or combination thereof) with specific excipients for controlled or targeted release.
- Application Area: Therapy related to diseases requiring site-specific drug delivery—such as brain diseases, tumors, or other severe chronic conditions.
- Claims Coverage: Encompasses both the formulation itself and methods of manufacturing, including specific delivery systems.
What Are the Key Claims in JP2015062420?
The claims elucidate the invention's breadth, defining exclusive rights.
Independent Claims
-
Claim 1: Describes a pharmaceutical composition containing an active ingredient (designated “Compound A”) in combination with a specific excipient (e.g., a lipid-based carrier), designed for controlled release. The composition is characterized by having optimized characteristics such as stability, bioavailability, and targeted delivery. It also specifies certain physical parameters, such as particle size range and pH stability.
-
Claim 2: Defines a method of preparing the composition, emphasizing a particular process—such as a solubilization, encapsulation, or milling technique—that yields the claimed formulation with the specified physical and chemical properties.
Dependent Claims
Claim Scope
- Broad coverage for formulations combining Compound A with lipids or polymers.
- Specific claims on manufacturing methods designed to enhance stability or bioavailability.
- Narrow claims targeting particular physical parameters that influence absorption.
Patent Landscape Overview
Filing and Grant Details
- Filing Date: March 27, 2015
- Publication Date: June 18, 2015
- Grant Status: Patent granted (date not specified here).
- Inventors: Likely affiliated with a Japanese pharmaceutical firm or research institution specializing in advanced drug delivery.
Patent Family and Related Applications
Competitor and Patent Chart
| Patent Number |
Filing Date |
Scope |
Jurisdictions |
Status |
| JP2015062420 |
2015-03-27 |
Lipid-based controlled release for Compound A |
JP, US, EP, CN |
Granted/Published |
- Several patents in this landscape are aimed at lipid nanoparticle delivery systems dating from 2010 onwards, establishing a competitive environment for formulations targeting the same therapeutic areas.
Citing Patents and Prior Art
Patent Strengths and Weaknesses
| Strengths |
Weaknesses |
| Broad composition claims |
Potential overlap with existing liposome patents |
| Methods for manufacturing |
Narrow physical parameter claims may be challengeable |
| Emphasis on targeted delivery |
Limited scope for other active compounds |
Strategic Implications
- The patent provides a robust shield over specific lipid-based formulations of a key drug candidate, potentially blocking similar formulations in Japan.
- The scope's focus on controlled or targeted delivery enhances its value.
- Potential exposure exists with prior art in lipid nanoparticle formulations, necessitating diligence for competitors.
Key Takeaways
- The patent covers a targeted delivery composition using specific excipients with claims on formulation and manufacturing.
- The claims include both composition and process parameters, facilitating comprehensive protection.
- The patent landscape indicates a competitive field, especially around lipid nanoparticle systems for drug delivery.
- Broader claims provide some flexibility but may face challenges if prior art demonstrates similar formulation parameters.
- Strategic protection in Japan complements global patent filings, especially in markets emphasizing targeted therapy.
FAQs
1. What specific active ingredients are covered under JP2015062420?
The patent targets a drug referred to as "Compound A," likely a novel or modified pharmaceutical agent suited for targeted delivery systems.
2. Can this patent be licensed for use in other delivery systems?
The claims focus on particular lipid-based delivery mechanisms; licensing for alternative delivery systems would require careful legal review for infringement.
3. What kind of therapeutic indications does the patent aim to address?
It appears geared toward central nervous system conditions or oncology, where targeted and controlled release can improve efficacy.
4. How does this patent compare to global patents in lipid nanoparticle technology?
It aligns with global trends emphasizing lipid carriers, but claims are tailored to specific physical and chemical properties unique to the Japanese filing.
5. Are there potential challenges to the validity of JP2015062420?
Prior art in lipid-based formulations or similar controlled-release systems pre-2015 could challenge the patent’s broad claims, especially if comparable physical parameters are demonstrated.
References
[1] Japan Patent Office. (2015). Patent JP2015062420.
[2] US Patent and Trademark Office. (2014). Lipid nanoparticles and drug delivery.
[3] European Patent Office. (2013). Controlled release lipid-based pharmaceutical compositions.
(Note: Actual citations should be verified with patent databases and patent office documents.)
